SEHK:6990Biotechs
Is Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Cheap On New Cancer Cell Research?
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has drawn investor attention after new translational research on its sac-TMT and osimertinib combination for EGFR-mutant non small cell lung cancer was published in the journal Cancer Cell.
See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.
The latest Cancer Cell publication and wider sac-TMT trial updates arrive as Sichuan Kelun-Biotech Biopharmaceutical trades at HK$467.6, with a year to date share price return of 16.72%...